Electroporation and use of hepatitis B virus envelope L proteins as bionanocapsules.
Hepatitis B virus (HBV) envelope L proteins, when synthesized in yeast cells, form a hollow bionanocapsule (BNC) in which genes (including large plasmids up to 40 kbp), small interfering RNA (siRNA), drugs, and proteins can be enclosed by electroporation. BNCs made from L proteins have several advantages as a delivery system: Because they display a human liver-specific receptor (the pre-S region of the L protein) on their surface, BNCs can efficiently and specifically deliver their contents to human liver-derived cells and tissues ex vivo (in cell culture) and in vivo (in a mouse xenograft model). Retargeting can be achieved simply by substituting other biorecognition molecules such as antibodies, ligands, receptors, and homing peptides for the pre-S region. In addition, BNCs have already been proven to be safe for use in humans during their development as an immunogen of hepatitis B vaccine. This protocol describes the loading of BNCs and their use in cell culture and in vivo.
Tadanori
T
Yamada
Joohee
J
Jung
Masaharu
M
Seno
Akihiko
A
Kondo
Masakazu
M
Ueda
Katsuyuki
K
Tanizawa
Shun'ichi
S
Kuroda
D000818:Animals; D004337:Drug Carriers / Q000493:pharmacokinetics*; D018274:Electroporation / Q000379:methods*; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D008099:Liver / Q000378:metabolism; D051379:Mice; D053758:Nanoparticles; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D012441:Saccharomyces cerevisiae / Q000235:genetics; D014759:Viral Envelope Proteins / Q000235:genetics / Q000378:metabolism*
D004337:Drug Carriers; C096362:L protein, hepatitis B virus; D011994:Recombinant Proteins; D014759:Viral Envelope Proteins